


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) A compound having formula (I):




(I)

in which:

R<sub>1</sub> is COOH<sub>i</sub>

Ar is




R<sub>2</sub> and R<sub>3</sub>, with the carbon atoms from which they attach [depend], form a

6-membered saturated ring;

R<sub>4</sub> is a lower alkyl radical;

R<sub>7</sub> represents a hydrogen atom, a halogen atom, a lower alkyl radical, a nitro

radical, a radical OR<sub>13</sub>, a polyether radical or a radical of the following formula:



$\text{R}_{13}$  represents a hydrogen atom or a lower alkyl radical;

$\text{R}_{14}$  and  $\text{R}_{15}$ , which may be identical or different, represent a hydrogen atom or a lower alkyl radical;

or a salt or isomer thereof.

2. (Previously Presented) A salt of a compound according to Claim 1, said salt being an alkali metal or alkaline-earth metal salt, zinc or organic amine salt, or a salt of an inorganic or organic acid.

3. (Previously Presented) A compound according to claim 1, containing a lower alkyl radical selected from the group consisting of methyl, ethyl, isopropyl, butyl, and tert-butyl radicals.

4-8. Cancelled.

4-9. (Previously Presented) A compound according to claim 1, containing a polyether radical selected from the group consisting of methoxymethyl ether, methoxyethoxymethyl ether, and methylthiomethyl ether radicals.

10-11. Cancelled.

5 ~~12.~~ (Previously Presented) A compound according to Claim 1, selected from the group consisting of:

6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-(4-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 2-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-[3-(5-hydroxypentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid,  
 6-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-[3-(3-carboxypropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid,  
 6-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid, and  
 6-[3-(2-hydroxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid.

13-14. Cancelled.

15. (Currently Amended) A method for treating dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation; for treating other types of keratinization disorder; for treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component; for treating inflammatory complaints which have no keratinization disorder; for treating all dermal or epidermal proliferations, whether benign or malignant and regardless of whether they are of viral origin; for treating other dermatological disorders including bullosis and collagen diseases; for treating ophthalmological disorders; ~~for repairing or combating ageing of the skin, whether this is light induced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing;~~ for curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy; for treating cicatrization disorders or repairing stretchmarks, or for promoting cicatrization; for combating disorders of sebaceous functioning hyperseborrhoea of acne or; for treating cancerous or precancerous states; for the treatment of inflammatory complaints; for the treatment of any general or skin complaint of viral origin; for the treatment of alopecia; ~~for the treatment of dermatological complaints having an immunological component;~~ for the treatment of complaints of the cardiovascular system; for the treatment of skin disorders due to an exposure to U.V. radiation, comprising administering to a subject an effective amount of the compound according to claim 1.

16. (Previously Presented) Pharmaceutical composition comprising, in a pharmaceutically acceptable support, at least one compound as defined in claim 1.

17. (Previously Presented) Composition according to Claim 16, wherein the concentration of compound(s) according to claim 1 is between 0.001% and 5% by weight relative to the composition as a whole.

6 18. (Previously Presented) Cosmetic composition comprising, in a cosmetically acceptable support, at least one compound as defined in claim 1.

7 19. (Previously Presented) Composition according to Claim 18, wherein the concentration of compound(s) is between 0.001% and 3% by weight relative to the composition as a whole.

8 20. (Previously Presented) A method for body or hair hygiene comprising administering an effective amount of the cosmetic composition according to claim 18<sup>6</sup> to a subject.